The association of liver fibrosis and chronic kidney disease in patients with metabolic associated fatty liver disease: A cross-sectional study

Rehab Badawi; Naglaa Samy Fahmy Abou Taira; Sara Essam Hasby; Walaa Elkhalawany; Waleed Elrefaey; Nahla Ahmed Khalf; Hanaa Ibrahim Okda

doi:10.15537/smj.2024.45.10.20240393

References

1.↵
1. Fernandez CJ,
2. Nagendra L,
3. Pappachan JM
. Metabolic dysfunction-associated fatty liver disease: an urgent call for global action. touchREV Endocrinol 2024; 20: 5-9.
OpenUrl
2.↵
1. Quetglas-Llabrés MM,
2. Monserrat-Mesquida M,
3. Bouzas C,
4. García S,
5. Mateos D,
6. Casares M, et al.
Effects of a 2-year lifestyle intervention on intrahepatic fat reduction and renal health: mitigation of inflammation and oxidative stress, a randomized trial. Antioxidants (Basel) 2024; 13: 754.
OpenUrl
3.↵
1. Eslam M,
2. Newsome PN,
3. Sarin SK,
4. Anstee QM,
5. Targher G,
6. Romero-Gomez M, et al.
A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol 2020; 73: 202-209.
OpenUrl CrossRef PubMed
4.↵
1. Lin S,
2. Huang J,
3. Wang M,
4. Kumar R,
5. Liu Y,
6. Liu S, et al.
Comparison of MAFLD and NAFLD diagnostic criteria in real world. Liver Int 2020; 40: 2082-2089.
OpenUrl PubMed
5.↵
Centers for Disease Control and Prevention. Chronic kidney disease in the United States. [Updated 2023; accessed 2023 Dec 15]. Available from: https://www.cdc.gov/kidneydisease/publications-resources/ckd-national-facts.html
6.↵
1. Stevens PE,
2. Ahmed SB,
3. Carrero JJ,
4. Foster B,
5. Francis A,
6. Hall RK, et al.
KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 2024; 105: S117-S314.
OpenUrl CrossRef
7.↵
1. Xiong S,
2. Wang P,
3. Yin S,
4. Deng W,
5. Zhao Y,
6. Li W, et al.
The association between liver fibrosis scores and chronic kidney disease. Front Med (Lausanne) 2023; 10: 1046825.
OpenUrl
8.↵
1. Lee HH,
2. Ro H,
3. Jung JY,
4. Chang JH,
5. Chung W,
6. Kim AJ
. The fatty liver index’s association with incident chronic kidney disease in Korean middle-aged adults:a community-based cohort study. J Clin Med 2024; 13: 1616.
OpenUrl
9.↵
1. Gurun M,
2. Brennan P,
3. Handjiev S,
4. Khatib A,
5. Leith D,
6. Dillon JF, et al.
Increased risk of chronic kidney disease and mortality in a cohort of people diagnosed with metabolic dysfunction associated steatotic liver disease with hepatic fibrosis. PLoS One 2024; 19: e0299507.
OpenUrl
10.
1. Orfanidou M,
2. Ntenti C,
3. Evripidou K,
4. Mataftsi A,
5. Goulas A,
6. Polyzos SA
. Retinal vascular lesions in patients with nonalcoholic fatty liver disease:a systematic review and meta-analysis. J Pers Med 2023; 13: 1148.
OpenUrl
11.↵
1. Yilmaz Y,
2. Zeybel M,
3. Adali G,
4. Cosar AM,
5. Sertesen E,
6. Gokcan H, et al.
TASL practice guidance on the clinical assessment and management of patients with nonalcoholic fatty liver disease. Hepatol Forum 2023; 4: 1-32.
OpenUrl
12.↵
1. Levey AS,
2. Stevens LA,
3. Schmid CH,
4. Zhang YL,
5. Castro AF 3rd.,
6. Feldman HI, et al.
A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-612.
OpenUrl CrossRef PubMed Web of Science
13.↵
1. Ferraioli G
. Quantitative assessment of liver steatosis using ultrasound controlled attenuation parameter (Echosens). J Med Ultrason (2001) 2021; 48: 489-495.
OpenUrl
14.↵
1. Hinkle DE,
2. Wiersma W,
3. Jurs SG
. Applied statistics for the behavioral sciences, 5th edition. [Updated 2003; 2023 May 22]. Available from: https://www.scirp.org/reference/referencespapers?referenceid=2229977
15.↵
1. Pal SC,
2. Méndez-Sánchez N
. Insulin resistance and adipose tissue interactions as the cornerstone of metabolic (dysfunction)-associated fatty liver disease pathogenesis. World J Gastroenterol 2023; 29: 3999-4008.
OpenUrl
16.↵
1. Hu Q,
2. Chen Y,
3. Bao T,
4. Huang Y
. Association of metabolic dysfunction-associated fatty liver disease with chronic kidney disease:a Chinese population-based study. Ren Fail 2022; 44: 1996-2005.
OpenUrl
17.↵
1. Deng Y,
2. Zhao Q,
3. Gong R
. Association between metabolic associated fatty liver disease and chronic kidney disease:a cross-sectional study from NHANES 2017-2018. Diabetes Metab Syndr Obes 2021; 14: 1751-1761.
OpenUrl
18.↵
1. Sun DQ,
2. Jin Y,
3. Wang TY,
4. Zheng KI,
5. Rios RS,
6. Zhang HY, et al.
MAFLD and risk of CKD. Metabolism 2021; 115: 154433.
OpenUrl
19.↵
1. Su W,
2. Chen M,
3. Xiao L,
4. Du S,
5. Xue L,
6. Feng R, et al.
Association of metabolic dysfunction-associated fatty liver disease, type 2 diabetes mellitus, and metabolic goal achievement with risk of chronic kidney disease. Front Public Health 2022; 10: 1047794.
OpenUrl
20.↵
1. Jang HR,
2. Kang D,
3. Sinn DH,
4. Gu S,
5. Cho SJ,
6. Lee JE, et al.
Nonalcoholic fatty liver disease accelerates kidney function decline in patients with chronic kidney disease:a cohort study. Sci Rep 2018; 8: 4718.
OpenUrl PubMed
21.↵
1. Sun DQ,
2. Targher G,
3. Byrne CD,
4. Wheeler DC,
5. Wong VW,
6. Fan JG, et al.
An international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney disease. Hepatobiliary Surg Nutr 2023; 12: 386-403.
OpenUrl CrossRef
22.
1. Akahane T,
2. Akahane M,
3. Namisaki T,
4. Kaji K,
5. Moriya K,
6. Kawaratani H, et al.
Association between non-alcoholic fatty liver disease and chronic kidney disease:a cross-sectional study. J Clin Med 2020; 9: 1635.
OpenUrl
23.
1. Hashimoto Y,
2. Hamaguchi M,
3. Okamura T,
4. Nakanishi N,
5. Obora A,
6. Kojima T, et al.
Metabolic associated fatty liver disease is a risk factor for chronic kidney disease. J Diabetes Investig 2022; 13: 308-316.
OpenUrl
24.↵
1. Byrne CD,
2. Targher G
. NAFLD as a driver of chronic kidney disease. J Hepatol 2020; 72: 785-801.
OpenUrl CrossRef PubMed

In this issue

Download PDF

Email Article

Citation Tools

Bookmark this article

Cited By...

No citing articles found.

Google Scholar

More in this TOC Section

Show more Original Article

Keywords

[1] 1.↵
Fernandez CJ,
Nagendra L,
Pappachan JM
. Metabolic dysfunction-associated fatty liver disease: an urgent call for global action. touchREV Endocrinol 2024; 20: 5-9.
OpenUrl

[2] Fernandez CJ,

[3] Nagendra L,

[4] Pappachan JM

[5] 2.↵
Quetglas-Llabrés MM,
Monserrat-Mesquida M,
Bouzas C,
García S,
Mateos D,
Casares M, et al.
Effects of a 2-year lifestyle intervention on intrahepatic fat reduction and renal health: mitigation of inflammation and oxidative stress, a randomized trial. Antioxidants (Basel) 2024; 13: 754.
OpenUrl

[6] Quetglas-Llabrés MM,

[7] Monserrat-Mesquida M,

[8] Bouzas C,

[9] García S,

[10] Mateos D,

[11] Casares M, et al.

[12] 3.↵
Eslam M,
Newsome PN,
Sarin SK,
Anstee QM,
Targher G,
Romero-Gomez M, et al.
A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol 2020; 73: 202-209.
OpenUrl CrossRef PubMed

[13] Eslam M,

[14] Newsome PN,

[15] Sarin SK,

[16] Anstee QM,

[17] Targher G,

[18] Romero-Gomez M, et al.

[19] 4.↵
Lin S,
Huang J,
Wang M,
Kumar R,
Liu Y,
Liu S, et al.
Comparison of MAFLD and NAFLD diagnostic criteria in real world. Liver Int 2020; 40: 2082-2089.
OpenUrl PubMed

[20] Lin S,

[21] Huang J,

[22] Wang M,

[23] Kumar R,

[24] Liu Y,

[25] Liu S, et al.

[26] 5.↵
Centers for Disease Control and Prevention. Chronic kidney disease in the United States. [Updated 2023; accessed 2023 Dec 15]. Available from: https://www.cdc.gov/kidneydisease/publications-resources/ckd-national-facts.html

[27] 6.↵
Stevens PE,
Ahmed SB,
Carrero JJ,
Foster B,
Francis A,
Hall RK, et al.
KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 2024; 105: S117-S314.
OpenUrl CrossRef

[28] Stevens PE,

[29] Ahmed SB,

[30] Carrero JJ,

[31] Foster B,

[32] Francis A,

[33] Hall RK, et al.

[34] 7.↵
Xiong S,
Wang P,
Yin S,
Deng W,
Zhao Y,
Li W, et al.
The association between liver fibrosis scores and chronic kidney disease. Front Med (Lausanne) 2023; 10: 1046825.
OpenUrl

[35] Xiong S,

[36] Wang P,

[37] Yin S,

[38] Deng W,

[39] Zhao Y,

[40] Li W, et al.

[41] 8.↵
Lee HH,
Ro H,
Jung JY,
Chang JH,
Chung W,
Kim AJ
. The fatty liver index’s association with incident chronic kidney disease in Korean middle-aged adults:a community-based cohort study. J Clin Med 2024; 13: 1616.
OpenUrl

[42] Lee HH,

[43] Ro H,

[44] Jung JY,

[45] Chang JH,

[46] Chung W,

[47] Kim AJ

[48] 9.↵
Gurun M,
Brennan P,
Handjiev S,
Khatib A,
Leith D,
Dillon JF, et al.
Increased risk of chronic kidney disease and mortality in a cohort of people diagnosed with metabolic dysfunction associated steatotic liver disease with hepatic fibrosis. PLoS One 2024; 19: e0299507.
OpenUrl

[49] Gurun M,

[50] Brennan P,

[51] Handjiev S,

[52] Khatib A,

[53] Leith D,

[54] Dillon JF, et al.

[55] 10.
Orfanidou M,
Ntenti C,
Evripidou K,
Mataftsi A,
Goulas A,
Polyzos SA
. Retinal vascular lesions in patients with nonalcoholic fatty liver disease:a systematic review and meta-analysis. J Pers Med 2023; 13: 1148.
OpenUrl

[56] Orfanidou M,

[57] Ntenti C,

[58] Evripidou K,

[59] Mataftsi A,

[60] Goulas A,

[61] Polyzos SA

[62] 11.↵
Yilmaz Y,
Zeybel M,
Adali G,
Cosar AM,
Sertesen E,
Gokcan H, et al.
TASL practice guidance on the clinical assessment and management of patients with nonalcoholic fatty liver disease. Hepatol Forum 2023; 4: 1-32.
OpenUrl

[63] Yilmaz Y,

[64] Zeybel M,

[65] Adali G,

[66] Cosar AM,

[67] Sertesen E,

[68] Gokcan H, et al.

[69] 12.↵
Levey AS,
Stevens LA,
Schmid CH,
Zhang YL,
Castro AF 3rd.,
Feldman HI, et al.
A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-612.
OpenUrl CrossRef PubMed Web of Science

[70] Levey AS,

[71] Stevens LA,

[72] Schmid CH,

[73] Zhang YL,

[74] Castro AF 3rd.,

[75] Feldman HI, et al.

[76] 13.↵
Ferraioli G
. Quantitative assessment of liver steatosis using ultrasound controlled attenuation parameter (Echosens). J Med Ultrason (2001) 2021; 48: 489-495.
OpenUrl

[77] Ferraioli G

[78] 14.↵
Hinkle DE,
Wiersma W,
Jurs SG
. Applied statistics for the behavioral sciences, 5th edition. [Updated 2003; 2023 May 22]. Available from: https://www.scirp.org/reference/referencespapers?referenceid=2229977

[79] Hinkle DE,

[80] Wiersma W,

[81] Jurs SG

[82] 15.↵
Pal SC,
Méndez-Sánchez N
. Insulin resistance and adipose tissue interactions as the cornerstone of metabolic (dysfunction)-associated fatty liver disease pathogenesis. World J Gastroenterol 2023; 29: 3999-4008.
OpenUrl

[83] Pal SC,

[84] Méndez-Sánchez N

[85] 16.↵
Hu Q,
Chen Y,
Bao T,
Huang Y
. Association of metabolic dysfunction-associated fatty liver disease with chronic kidney disease:a Chinese population-based study. Ren Fail 2022; 44: 1996-2005.
OpenUrl

[86] Hu Q,

[87] Chen Y,

[88] Bao T,

[89] Huang Y

[90] 17.↵
Deng Y,
Zhao Q,
Gong R
. Association between metabolic associated fatty liver disease and chronic kidney disease:a cross-sectional study from NHANES 2017-2018. Diabetes Metab Syndr Obes 2021; 14: 1751-1761.
OpenUrl

[91] Deng Y,

[92] Zhao Q,

[93] Gong R

[94] 18.↵
Sun DQ,
Jin Y,
Wang TY,
Zheng KI,
Rios RS,
Zhang HY, et al.
MAFLD and risk of CKD. Metabolism 2021; 115: 154433.
OpenUrl

[95] Sun DQ,

[96] Jin Y,

[97] Wang TY,

[98] Zheng KI,

[99] Rios RS,

[100] Zhang HY, et al.

[101] 19.↵
Su W,
Chen M,
Xiao L,
Du S,
Xue L,
Feng R, et al.
Association of metabolic dysfunction-associated fatty liver disease, type 2 diabetes mellitus, and metabolic goal achievement with risk of chronic kidney disease. Front Public Health 2022; 10: 1047794.
OpenUrl

[102] Su W,

[103] Chen M,

[104] Xiao L,

[105] Du S,

[106] Xue L,

[107] Feng R, et al.

[108] 20.↵
Jang HR,
Kang D,
Sinn DH,
Gu S,
Cho SJ,
Lee JE, et al.
Nonalcoholic fatty liver disease accelerates kidney function decline in patients with chronic kidney disease:a cohort study. Sci Rep 2018; 8: 4718.
OpenUrl PubMed

[109] Jang HR,

[110] Kang D,

[111] Sinn DH,

[112] Gu S,

[113] Cho SJ,

[114] Lee JE, et al.

[115] 21.↵
Sun DQ,
Targher G,
Byrne CD,
Wheeler DC,
Wong VW,
Fan JG, et al.
An international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney disease. Hepatobiliary Surg Nutr 2023; 12: 386-403.
OpenUrl CrossRef

[116] Sun DQ,

[117] Targher G,

[118] Byrne CD,

[119] Wheeler DC,

[120] Wong VW,

[121] Fan JG, et al.

[122] 22.
Akahane T,
Akahane M,
Namisaki T,
Kaji K,
Moriya K,
Kawaratani H, et al.
Association between non-alcoholic fatty liver disease and chronic kidney disease:a cross-sectional study. J Clin Med 2020; 9: 1635.
OpenUrl

[123] Akahane T,

[124] Akahane M,

[125] Namisaki T,

[126] Kaji K,

[127] Moriya K,

[128] Kawaratani H, et al.

[129] 23.
Hashimoto Y,
Hamaguchi M,
Okamura T,
Nakanishi N,
Obora A,
Kojima T, et al.
Metabolic associated fatty liver disease is a risk factor for chronic kidney disease. J Diabetes Investig 2022; 13: 308-316.
OpenUrl

[130] Hashimoto Y,

[131] Hamaguchi M,

[132] Okamura T,

[133] Nakanishi N,

[134] Obora A,

[135] Kojima T, et al.

[136] 24.↵
Byrne CD,
Targher G
. NAFLD as a driver of chronic kidney disease. J Hepatol 2020; 72: 785-801.
OpenUrl CrossRef PubMed

[137] Byrne CD,

[138] Targher G

Main menu

User menu

Search

The association of liver fibrosis and chronic kidney disease in patients with metabolic associated fatty liver disease

A cross-sectional study

References

In this issue

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Similar Articles

Keywords

CONTENT

JOURNAL

AUTHORS

Main menu

User menu

Search

The association of liver fibrosis and chronic kidney disease in patients with metabolic associated fatty liver disease

A cross-sectional study

References

In this issue

Citation Manager Formats

Jump to section

Related Articles

Cited By...

More in this TOC Section

Similar Articles

Keywords

CONTENT

JOURNAL

AUTHORS